Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 8
HOS-147518 · Präparat HOS-099678
In the Phase 3 trial B7471014 (Study 1014), 831 participants 15 months to less than 18 years of age
received a single dose of Prevenar 20 in 4 age groups (209 participants 15 to less than 24 months of
age; 216 participants 2 years to less than 5 years of age; 201 participants 5 years to less than 10 years
age; and 205 participants 10 years to less than 18 years of age). The participants less than 5 years of
age had received at least 3 prior doses of Prevenar 13.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage f09aaab498ce85806b623c7f1d2f6899818efb813d0526d1659dc3902802c2da · Zeichen 3944–4410 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 8
HOS-147519 · Präparat HOS-099678
The most frequently reported (> 10%) adverse reactions observed after any dose of Prevenar 20 in
participants less than 2 years of age were irritability (61.8%), pain at the injection site (52.5%),
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 6adf4113183e11e3731e2b7ff1f4959054b5c318146cf62c4f1bb233c7c4313b · Zeichen 4412–4609 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 8–9
HOS-147520 · Präparat HOS-099678
8
drowsiness/increased sleep (41.7%), redness at the injection site (37.7%), decreased appetite (25.0%),
swelling at the injection site (22.1%), and fever ≥ 38.0 °C (11.8%). In participants aged 2 years and
older, the most frequently reported adverse reactions were pain at the injection site (66.0% to 82.9%),
muscle pain (26.5% to 48.3%), redness at the injection site (15.1% to 39.1%), fatigue (27.8% to
37.2%), headache (5.6% to 29.3%), and swelling at the injection site (15.6% to 27.1%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 893e2296b0da6d58e8a8e052ebb33814cb08e9493c17361964254797d3fe561f · Zeichen 4664–5158 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147521 · Präparat HOS-099678
Participants 18 years of age and older
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage b4412079695b9ad6cb6a4ec085d7402243f0f8d6c0245f9df3adbd6984b847d7 · Zeichen 5160–5198 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147522 · Präparat HOS-099678
The safety of Prevenar 20 was evaluated in 4 552 participants 18 years of age and older in 6 clinical
trials (two Phase 1, one Phase 2, and three Phase 3), and 2 496 participants in the control groups.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage cbe7120d8aa35a37bd26ad37ff6634b284ea41f019a13a90f876334d55955e4f · Zeichen 5200–5401 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147523 · Präparat HOS-099678
In the Phase 3 trials, 4 263 participants received Prevenar 20. This included 1 798 participants 18
through 49 years of age, 334 participants 50 through 59 years of age, and 2 131 participants 60 years
of age and older (1 138 were 65 years of age and older). Of the participants who received Prevenar 20
in the Phase 3 trials, 3 639 were naïve to pneumococcal vaccines, 253 had previously received
Pneumovax 23 (pneumococcal polysaccharide vaccine [23-valent]; PPSV23) (≥ 1 to ≤ 5 years prior to
enrolment), 246 had previously received Prevenar 13 only (≥ 6 months prior to enrolment), and 125
had previously received Prevenar 13 followed by PPSV23 (the dose of PPSV23 ≥ 1-year prior to
enrolment).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 4844de3386c735aa1df4665ccb2f0ab182572cc91b7a1f146de7cbb4e8317803 · Zeichen 5403–6101 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147524 · Präparat HOS-099678
Participants in the Phase 3 trial B7471007 (Pivotal Study 1007) were evaluated for adverse events for
1 month after vaccination, and serious adverse events through 6 months after vaccination. This study
included 447 participants 18 to 49 years of age, 445 participants 50 to 59 years of age,
1 985 participants 60 to 64 years of age, 624 participants 65 to 69 years of age, 319 participants 70 to
79 years of age, and 69 participants ≥ 80 years of age.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 385e438d7ce43c1756700d6b64ca42ce1a91ac210ab8b519927d9d4805bca9dd · Zeichen 6103–6555 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147525 · Präparat HOS-099678
In participants 18 to 49 years of age in Studies 1007 and a Phase 3 trial B7471008 (Lot Consistency
Study 1008), the most frequently reported adverse reactions were pain at injection site (79.2%),
muscle pain (62.9%), fatigue (46.7%), headache (36.7%), and joint pain (16.2%). In participants 50 to
59 years of age in Study 1007, the most frequently reported adverse reactions were pain at injection
site (72.5%), muscle pain (49.8%), fatigue (39.3%), headache (32.3%), and joint pain (15.4%). In
participants ≥ 60 years of age in Study 1007, the most frequently reported adverse reactions were pain
at injection site (55.4%), muscle pain (39.1%), fatigue (30.2%), headache (21.5%), and joint pain
(12.6%). These were usually mild or moderate in intensity and resolved within a few days after
vaccination.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 6d176a7c60e957855926ac9f8b264fc479ef97ec168f51ca3d5fc4e65072e32c · Zeichen 6557–7362 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147526 · Präparat HOS-099678
Phase 3 Study B7471006 (Study 1006) evaluated Prevenar 20 in participants ≥ 65 years of age with
varying prior pneumococcal status (prior PPSV23, prior Prevenar 13 or prior Prevenar 13 followed by
PPSV23). In this study, the most frequently reported adverse reactions for participants were similar in
frequency to those described for participants ≥ 60 years of age in Study 1007, with slightly higher
injection site pain (61.2%) in participants with prior Prevenar 13, and joint pain (16.8%) in
participants with prior Prevenar 13 followed by PPSV23.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage acaa4a48ffaa840971c6b26911d8e6daccbccbcaa55b217c426c39e0c046d518 · Zeichen 7364–7914 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147527 · Präparat HOS-099678
Tabulated list of adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage d51c90b617391dca447a849e03c6ddac1785fb6a36da5cf3e36f8f60e5aed8a9 · Zeichen 7916–7951 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147528 · Präparat HOS-099678
Tabulated lists of adverse reactions from the infant Phase 2, Phase 3 clinical trials in paediatric and
adult populations, and postmarketing experience are presented below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 6fb55013103009a1627c5855141729008c7cfc18dba51236bd5db7be6189d165 · Zeichen 7953–8125 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9–10
HOS-147529 · Präparat HOS-099678
9
Adverse reactions from clinical trials
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 4c618748fdd8cf6b7f9af1c7a7e0b49174e870a164a60f99a0d94ee227185215 · Zeichen 8182–8223 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 10
HOS-147530 · Präparat HOS-099678
As Prevenar 20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the
same vaccine excipients as Prevenar 13, the adverse reactions already identified for Prevenar 13 have
been adopted for Prevenar 20. Table 1 presents adverse reactions reported in the Phase 2 infant trial,
and the Phase 3 trials in paediatric and adult populations, based on the highest frequency among
adverse reactions, local reactions, or systemic events, after vaccination in an Prevenar 20 group or
integrated dataset. The data from clinical trials in infants reflect Prevenar 20 administered
simultaneously with other routine childhood vaccines.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 225eea276a3b472f4f8583451ac369c6144ffb29fb8d7cda2e736220425dc3af · Zeichen 8225–8872 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 10
HOS-147531 · Präparat HOS-099678
Adverse reactions are listed by system organ class in decreasing order of frequency and seriousness.
The frequency is defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon
(≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), not known (cannot be
estimated from available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage b01dbbb809fb023a83dceeedfe9f68cc36882e672df406ad951cfdc21696e7d2 · Zeichen 8874–9203 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 10
HOS-147532 · Präparat HOS-099678
Table 1. Tabulated Adverse Reactions From Prevenar 20 Clinical Trials
System Organ Adverse Reactions Frequency
Class
Infants/Children/Adolescents Adults
6 weeks to less 5 years to less
than 5 years of than 18 years
age of age
Immune System Hypersensitivity Rarea - Uncommon
Disorders reaction including
face oedema,
dyspnoea,
bronchospasm
Metabolism and Decreased appetite Very common Very commona Very
Nutrition commona
Disorders
Psychiatric Irritability Very common Very commona -
Disorders Crying Uncommona - -
Nervous Drowsiness/increased Very common Very commona -
System sleep
Disorders Seizures (including Uncommon - -
febrile seizures)
Hypotonic- Rarea - -
hyporesponsive
episode
Restless Very commona Very commona -
sleep/decreased sleep
Headache - Very common Very
common
Gastrointestinal Diarrhoea Common Commona Uncommonb
Disorders Nausea - - Uncommon
Vomiting Common Commona Uncommonb
Skin and Rash Common Commona Uncommonb
Subcutaneous Angioedema - - Uncommon
Tissue Urticaria or urticaria- Uncommon Uncommon -
Disorders like rash
Musculoskeletal Muscle pain - Very common Very
and connective common
tissue Disorders Joint pain - Common Very
common
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage ccab9e206ec6425c8a8accced50f17c1fe6da6ff763992fb52ac1a18ec947423 · Zeichen 9206–11981 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 10–11
HOS-147533 · Präparat HOS-099678
10
Table 1. Tabulated Adverse Reactions From Prevenar 20 Clinical Trials
System Organ Adverse Reactions Frequency
Class
Infants/Children/Adolescents Adults
6 weeks to less 5 years to less
than 5 years of than 18 years
age of age
General Fever (pyrexia) Very common Uncommon Common
Disorders and Fever greater than Common - -
Administration 38.9 °C
Site Conditions Fatigue - Very common Very
common
Vaccination-site Very common Very common Commonb
erythema
Vaccination-site Very common Very common Commonb
induration/swelling
Vaccination-site Very common - -
erythema or (after toddler dose
induration/swelling and in older
(> 2.0-7.0 cm) children [age 2 to
< 5 years])
Common (after - -
infant series)
Vaccination-site Uncommon - -
erythema or
induration/swelling
(> 7.0 cm)
Vaccination-site Very common Very common Very
pain/tenderness common
Vaccination-site Common Common Very
pain/tenderness commona
causing limitation of
limb movement
Vaccination-site - - Uncommon
pruritus
Lymphadenopathy - - Uncommon
Vaccination-site - - Uncommon
urticaria
Chills - - Uncommonb
Vaccination-site Rarec - -
hypersensitivity
a. These frequencies are based on adverse reactions (ARs) reported in clinical trials with Prevenar 13 as these ARs
were not reported in Prevenar 20 trials of infants (Phase 2 and 3), children and adolescents less than 18 years of age,
and adults 18 years and older (Phase 3); therefore, the frequency is not known.
b. Event reported from clinical trials in adults with Prevenar 13 with very common frequency (≥ 1/10).
c. AR not reported for Prevenar 13, although injection-site urticaria, injection-site pruritus, and injection-site
dermatitis were reported in Prevenar 13 postmarketing experience.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage ca5a10a208d17895fa14c22f21d9dfc15630c5f530c0f4c6a6f878fc4b750236 · Zeichen 12033–15997 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 11
HOS-147534 · Präparat HOS-099678
Safety with concomitant vaccine administration in adults
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 4f6aa5963fe9d64afce6ccbec33c71520682b1b36ee1ec7224c209d10e9eb823 · Zeichen 15999–16055 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 11
HOS-147535 · Präparat HOS-099678
When Prevenar 20 was administered to adults aged ≥ 65 years together with the third (booster) dose of
a COVID-19 mRNA vaccine (nucleoside modified), the tolerability profile generally resembled that of
the COVID-19 mRNA vaccine (nucleoside modified) administered alone. There were a few
differences in the safety profile when compared to administration of Prevenar 20 alone. In the Phase 3
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage c5535abe4a8f7d07c38a71fd171ddbc707fabf63b089dfadec3010630d029242 · Zeichen 16057–16446 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 11–12
HOS-147536 · Präparat HOS-099678
11
trial B7471026 (Study 1026), pyrexia (13.0%) and chills (26.5%) were reported as “very common”
with co-administration. There was also 1 report of dizziness (0.5%) in the co-administration group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage eda4cf924922aa99a8189b2ddc263eb920c93f8e1591d79d102b401334ce7efa · Zeichen 16511–16709 im Abschnitt
Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 12
HOS-147537 · Präparat HOS-099678
Adverse reactions from postmarketing experience
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage 396f5aee14501ae34e960e76b16c086b71c4afc13c783300eacaffbec8681d85 · Zeichen 16711–16758 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.